Treating exposure to chemical warfare agents: implications for health care providers and community emergency planning.

N B Munro, A P Watson, K R Ambrose, and G D Griffin

Author information ► Copyright and License information ►

This article has been cited by other articles in PMC.

Abstract

Current treatment protocols for exposure to nerve and vesicant agents found in the U.S. stockpile of unitary chemical weapons are summarized, and the toxicities of available antidotes are evaluated. The status of the most promising of the new nerve agent antidotes is reviewed. In the U.S. atropine and pralidoxime compose the only approved antidote regimen for organophosphate nerve agent poisoning. Diazepam may also be used if necessary to control convulsions. To avoid death, administration must occur within minutes of substantial exposure together with immediate decontamination. Continuous observation and repeated administration of antidotes are necessary as symptoms warrant. Available antidotes do not necessarily prevent respiratory failure or incapacitation. The toxicity of the antidotes themselves and the individualized nature of medical care preclude recommending that autoinjectors be distributed to the general public. In addition, precautionary administration of protective drugs to the general population would not be feasible or desirable. No antidote exists for poisoning by the vesicant sulfur mustard (H, HD, HT); effective intervention can only be accomplished by rapid decontamination followed by palliative treatment of symptoms. British anti-Lewisite (BAL) (2,3-dimercapto-1-propanolol) is the antidote of choice for treatment of exposure to Lewisite, another potent vesicant. Experimental water-soluble BAL analogues have been developed that are less toxic than BAL. Treatment protocols for each antidote are summarized in tabular form for use by health care providers.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.4M), or click on a page image below to browse page by page. Links to PubMed are also available forSelected References.

 

205

206

207

208

209

210

211

212

213

214

215

 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

• Carnes SA, Watson AP. Disposing of the US chemical weapons stockpile. An approaching reality. JAMA.1989 Aug 4;262(5):653–659. [PubMed]
• Hu H, Cook-Deegan R, Shukri A. The use of chemical weapons. Conducting an investigation using survey epidemiology. JAMA. 1989 Aug 4;262(5):640–643. [PubMed]
• Orient JM. Chemical and biological warfare. Should defenses be researched and deployed? JAMA. 1989 Aug 4;262(5):644–648. [PubMed]
• GROB D, HARVEY AM. The effects and treatment of nerve gas poisoning. Am J Med. 1953 Jan;14(1):52–63. [PubMed]
• Dunn MA, Sidell FR. Progress in medical defense against nerve agents. JAMA. 1989 Aug 4;262(5):649–652. [PubMed]
• Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol. 1974;7(1):1–17. [PubMed]
• KROP S, KUNKEL AM. Observations on pharmacology of the anticholinesterases sarin and tabun. Proc Soc Exp Biol Med. 1954 Jul;86(3):530–533. [PubMed]
• Meeter E, Wolthuis OL. The effects of cholinesterase inhibitors on the body temperature of the rat. Eur J Pharmacol. 1968 Aug;4(1):18–24. [PubMed]
• Sidell FR, Groff WA. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol. 1974 Feb;27(2):241–252. [PubMed]
• Bosković B, Kovacević V, Jovanović D. PAM-2 Cl, HI-6, and HGG-12 in soman and tabun poisoning.Fundam Appl Toxicol. 1984 Apr;4(2 Pt 2):S106–S115. [PubMed]
• Calesnick B, Christensen, Richter M. Human toxicity of various oximes. 2-Pyridine aldoxime methyl chloride, its methane sulfonate salt, and 1,1'-trimethylenebis-(4-formylpyridinium chloride). Arch Environ Health. 1967 Nov;15(5):599–608. [PubMed]
• McLeod CG., Jr Pathology of nerve agents: perspectives on medical management. Fundam Appl Toxicol.1985 Dec;5(6 Pt 2):S10–S16. [PubMed]
• Bosković B. The treatment of Soman poisoning and its perspectives. Fundam Appl Toxicol. 1981 Mar-Apr;1(2):203–213. [PubMed]
• Martin LJ, Doebler JA, Shih TM, Anthony A. Protective effect of diazepam pretreatment on soman-induced brain lesion formation. Brain Res. 1985 Jan 28;325(1-2):287–289. [PubMed]
• Inns RH, Leadbeater L. The efficacy of bispyridinium derivatives in the treatment of organophosphonate poisoning in the guinea-pig. J Pharm Pharmacol. 1983 Jul;35(7):427–433. [PubMed]
• Gall D. The use of therapeutic mixtures in the treatment of cholinesterase inhibition. Fundam Appl Toxicol.1981 Mar-Apr;1(2):214–216. [PubMed]
• Kiffer D, Minard P. Reactivation by imidazo-pyridinium oximes of acetylcholinesterase inhibited by organophosphates. A study with an immobilized enzyme method. Biochem Pharmacol. 1986 Aug 1;35(15):2527–2533. [PubMed]
• Heldman E, Ashani Y, Raveh L, Rachaman ES. Sugar conjugates of pyridinium aldoximes as antidotes against organophosphate poisoning. Carbohydr Res. 1986 Aug 15;151:337–347. [PubMed]
• Leadbeater L, Inns RH, Rylands JM. Treatment of poisoning by soman. Fundam Appl Toxicol. 1985 Dec;5(6 Pt 2):S225–S231. [PubMed]
• Wolfe AD, Rush RS, Doctor BP, Koplovitz I, Jones D. Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam Appl Toxicol. 1987 Aug;9(2):266–270. [PubMed]
• Lenz DE, Brimfield AA, Hunter KW, Jr, Benschop HP, de Jong LP, van Dijk C, Clow TR. Studies using a monoclonal antibody against soman. Fundam Appl Toxicol. 1984 Apr;4(2 Pt 2):S156–S164. [PubMed]
• Maxwell DM, Brecht KM, O'Neill BL. The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol Lett. 1987 Nov;39(1):35–42. [PubMed]
• Little JS, Broomfield CA, Fox-Talbot MK, Boucher LJ, MacIver B, Lenz DE. Partial characterization of an enzyme that hydrolyzes sarin, soman, tabun, and diisopropyl phosphorofluoridate (DFP). Biochem Pharmacol. 1989 Jan 1;38(1):23–29. [PubMed]
• Watson AP, Jones TD, Griffin GD. Sulfur mustard as a carcinogen: application of relative potency analysis to the chemical warfare agents H, HD, and HT. Regul Toxicol Pharmacol. 1989 Aug;10(1):1–25.[PubMed]
• Dahl H, Gluud B, Vangsted P, Norn M. Eye lesions induced by mustard gas. Acta Ophthalmol Suppl.1985;173:30–31. [PubMed]
• Vojvodić V, Milosavljević Z, Bosković B, Bojanić N. The protective effect of different drugs in rats poisoned by sulfur and nitrogen mustards. Fundam Appl Toxicol. 1985 Dec;5(6 Pt 2):S160–S168.[PubMed]
• KLIMOVA LK. K farmakologii novogo antidota unitiola. Farmakol Toksikol. 1958 May-Jun;21(3):53–59. [PubMed]
• Slighter RG, Montenaro MJ, Fabian RJ, Bhandari JC, Donikian MR, Drobeck HP. Comparative nephrotoxicity of hydroxygentamicin and other aminoglycosides in rats. Fundam Appl Toxicol. 1984 Aug;4(4):558–567. [PubMed]
• Lenz K, Hruby K, Druml W, Eder A, Gaszner A, Kleinberger G, Pichler M, Weiser M. 2,3-Dimercaptosuccinic acid in human arsenic poisoning. Arch Toxicol. 1981 Jun;47(3):241–243. [PubMed]
• Clarkson TW, Magos L, Cox C, Greenwood MR, Amin-Zaki L, Majeed MA, Al-Damluji SF. Tests of efficacy of antidotes for removal of methylmercury in human poisoning during the Iraq outbreak. J Pharmacol Exp Ther. 1981 Jul;218(1):74–83. [PubMed]
• Friedheim E, Graziano JH, Popovac D, Dragovic D, Kaul B. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet. 1978 Dec 9;2(8102):1234–1236. [PubMed]
• Danielli JF, Danielli M, Fraser JB, Mitchell PD, Owen LN, Shaw G. BAL-INTRAV: a new non-toxic thiol for intravenous injection in arsenical poisoning: 1. Biological observations. 2. Chemical observations.Biochem J. 1947;41(3):325–333. [PMC free article] [PubMed]

---

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science